News & Media
Press Releases
July 7, 2026
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now EnrollingOragenics advances ONP-002 with full Australian trial enrollment and a new FDA engagement milestone.
May 7, 2026
Oragenics Signs Letter of Intent to License CardioDialysis™ TechnologyCompany announces letter of intent expanding its CNS platform portfolio.
April 13, 2026
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002First patient dosed at Mackay Base Hospital in Australia within days of site activation.
March 17, 2026
Oragenics Files Annual Report on Form 10-KOragenics files annual report with the SEC and updates shareholders on clinical and strategic progress.
October 21, 2025
Oragenics Regains Full NYSE American ComplianceCompany confirms full compliance with NYSE American continued listing standards.
Media Coverage
Q2 2026 — TraderTV
Oragenics CEO on TraderTV — ONP-002 Phase 2a LaunchCEO Janet Huffman discusses the Phase 2a trial launch, the concussion treatment market, and Oragenics’ CNS platform strategy.
Q2 2026 — TraderTV
Oragenics on TraderTV — CNS Platform & Pipeline ExpansionCEO Janet Huffman and CMO Dr. James P. Kelly discuss the company’s broader CNS platform, Receptor.AI collaboration, and pipeline development strategy.
Investor Presentations
Investor Deck — Spring 2026
Current corporate overview and investment thesis presentation.
Annual Report / 10-K — 2025
Full annual report filed with the SEC.
Corporate Overview / Fact Sheet
One-page company summary for investors and media.
SEC Filings
Oragenics files reports with the U.S. Securities and Exchange Commission as required by federal securities laws. All filings are available on the SEC’s EDGAR database.
Annual Reports (10-K)
Comprehensive annual financial and operational reports filed with the SEC.
View on EDGAR →Stay Informed
Subscribe to receive Oragenics press releases and company updates directly to your inbox.
For investor and media inquiries, contact irth Communications directly at ir@oragenics.com
Contact Us to SubscribeA dedicated email subscription platform will be added once confirmed. In the meantime, contact us directly to be added to our distribution list.